BioMarin Pharmaceutical(BMRN) - 2023 Q2 - Earnings Call Transcript

Your next question comes from the line of Paul Matteis from Stifel. Your line is now open. Paul Matteis Hey, thanks so much for taking my question. On VOXZOGO, Jeff, does the supply issue or, I guess, capacity issue temporarily impact how you market the drug? And how might that impact the way you sort of seek to interact with health care providers and patients if and when the label is expanded before the capacity constraint is fully resolved. And then on ROCTAVIAN just in terms of the timing, the 2- to 5-mo ...